CT导向下^(125)I粒子植入治疗肺癌患者的临床价值

The clinical value of CT guided ^(125)I particle implantation treatment in patients with lung cancer

目的探讨CT导向下^(125)I粒子植入治疗肺癌患者的临床价值。方法肺癌患者57例采用CT导向下^(125)I粒子植入,观察植入术后1个月和术后3个月疗效,术前、术后1个月和术后3个月外周血T淋巴细胞亚群变化及术后并发症发生情况。结果术后3个月总有效率为85. 96%,术后1个月为82. 46%,差异无统计学意义(P> 0. 05)。术后3个月CD3+[(51. 09±3. 68)%]、CD4+[(37. 56±2. 09)%]和CD4+/CD8+[(1. 09±0. 15)%]高于术后1个月CD3+[(45. 79±3. 12)%]、CD4+[(34. 10±2. 18)%]和CD4+/CD8+(0. 81±0. 12)(P <0. 05)。术后并发症发生率为10. 53%。结论 CT导向下^(125)I粒子植入治疗肺癌患者疗效明显,对患者细胞免疫功能无明显影响,且术后并发症发生率低。

Objective To explore the clinical value of CT guided 125 I particle implantation in the treatment of patients with lung cancer. Methods 57 patients with lung cancer were selected,and 125 I particles were implanted under the guidance of CT. The efficacy of CT guided 125 I seed implantation postoperative 1 months and postoperative 3 months were observed. The changes of T lymphocyte subsets and postoperative complications in peripheral blood before operation,postoperative 1 month and postoperative 3 months were observed. Results The total effective rate was 85. 96% at third months after operation and 82. 46% at first month after operation（P 0. 05）. 3 months after the operation,CD3＋（51. 09 ± 3. 68） %,CD4＋（37. 56 ± 2. 09） % and CD4＋/CD8＋（1. 09 ± 0. 15） were higher than those at 1 months after the operation of CD3＋（45. 79 ± 3. 12） %,CD4＋（34. 10 ± 2. 18） % and CD4＋/CD8＋（0. 81 ± 0. 12） %（P 0. 05）. The incidence of complications after CT guided 125 I implantation in 57 patients with lung cancer was 10. 53%.Conclusion The effect of CT guided 125 I implantation in the treatment of lung cancer patients is significant,and there is no obvious effect on the cellular immune function of the patients,and the incidence of postoperative complications is low.